2017
Smoking, APOE Genotype, and Cognitive Decline: the Rotterdam Study
Publication
Publication
Journal of Alzheimer's Disease , Volume 57 - Issue 4 p. 1191- 1195
The association of smoking with preclinical cognitive decline remains unclear and may be modified by the APOE ϵ4 genotype. In 5,705 participants (mean age: 63.9±9.1 years; 57.4 women) from the population-based Rotterdam Study, we investigated the relationship between smoking and cognitive decline over a 5.5-year period and examined potential effect modification by APOE ϵ4 genotype. We found that current smoking was related to decline in global cognition [difference compared to never smoking: -0.06 (95 C.I.-0.10;-0.01)], as well as decline on specific cognitive tests including the Letter Digit Substitution Task, the 15-Word Learning Test, and the Purdue Pegboard. We found no evidence for effect modification by APOE ϵ4 genotype on this relation.
| Additional Metadata | |
|---|---|
| , , , | |
| doi.org/10.3233/JAD-170063, hdl.handle.net/1765/99412 | |
| Journal of Alzheimer's Disease | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Wingbermühle, R., Wen, K.-X., Wolters, F., Ikram, A., & Bos, D. (2017). Smoking, APOE Genotype, and Cognitive Decline: the Rotterdam Study. Journal of Alzheimer's Disease, 57(4), 1191–1195. doi:10.3233/JAD-170063 |
|